Stockreport

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia [Yahoo! Finance]

Reviva Pharmaceuticals Holdings, Inc.  (RVPH) 
PDF Current data package highlights long-term safety profile, broad-spectrum clinical activity, and favorable adherence observed to date for once daily brilaroxazine over u [Read more]